Is CBAY or EQR a better dividend investment in 2026?

CBAY currently yields 6.16% with a 5% 5-year dividend growth rate. EQR yields 4.73% with 5% growth. The better choice depends on your goal: CBAY offers higher current income.

What is the dividend yield difference between CBAY and EQR?

CBAY has a forward dividend yield of 6.16% ($2.00/share annually). EQR yields 4.73% ($2.77/share annually). The yield gap is 1.43 percentage points.

Home › Compare › CBAY vs EQR

CBAY vs EQR: Dividend Comparison 2026

CBAY yields 6.16% · EQR yields 4.73%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 EQR wins by $10.4K in total portfolio value· pulled ahead in Year 3

INVESTMENT

TIME HORIZON10 years

CBAY

● Live price

6.16%

Share price

$32.48

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.0K

Annual income

$911.52

Full CBAY calculator →

EQR

● Live price

4.73%

Share price

$58.58

Annual div

$2.77

5Y div CAGR

15.8%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$40.5K

Annual income

$3,819.61

Full EQR calculator →

Portfolio growth — CBAY vs EQR

📍 EQR pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CBAY	EQR
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CBAY + EQR cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CBAY pays

EQR pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CBAY

Annual income on $10K today (after 15% tax)

$523.40/yr

After 10yr DRIP, annual income (after tax)

$774.79/yr

EQR

Annual income on $10K today (after 15% tax)

$401.93/yr

After 10yr DRIP, annual income (after tax)

$3,246.67/yr

At 15% tax rate, EQR beats the other by $2,471.88/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CBAY + EQR for your $10,000?

CBAY: 50%EQR: 50%

100% EQR50/50100% CBAY

Portfolio after 10yr

$35.2K

Annual income

$2,365.56/yr

Blended yield

6.71%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

CBAY

Analyst Ratings

Buy

Hold

Consensus: Hold

Altman Z

12.9

Piotroski

4/9

EQR

Analyst Ratings

Buy

Hold

Sell

Consensus: Hold

Price Target

$70.35

+20.1% upside vs current

Range: $63.00 — $78.50

Altman Z

1.8

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CBAY buys

EQR buys

No recent congressional trades found for CBAY or EQR in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCBAYEQR

Forward yield	6.16% ✓	4.73%
Annual dividend / share	$2.00	$2.77 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	15.8% ✓
Portfolio after 10y	$30.0K	$40.5K ✓
Annual income after 10y	$911.52	$3,819.61 ✓
Total dividends collected	$7.7K	$16.9K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	REIT
Analyst consensus	Hold	Hold

Year-by-year: CBAY vs EQR ($10,000, DRIP)

Year	CBAY Portfolio	CBAY Income/yr	EQR Portfolio	EQR Income/yr	Gap
1	$11,316	$615.76	$11,248	$547.57	+$68.00 → CBAY
2	$12,759	$651.20	$12,701	$666.53	+$58.00 → CBAY
3← crossover	$14,338	$686.22	$14,405	$814.59	$67.00 → EQR
4	$16,063	$720.72	$16,413	$999.84	$350.00 → EQR
5	$17,942	$754.57	$18,795	$1,232.92	$853.00 → EQR
6	$19,985	$787.70	$21,639	$1,527.95	$1.7K → EQR
7	$22,204	$820.02	$25,057	$1,903.80	$2.9K → EQR
8	$24,610	$851.47	$29,197	$2,385.87	$4.6K → EQR
9	$27,215	$881.98	$34,250	$3,008.70	$7.0K → EQR
10	$30,031	$911.52	$40,467	$3,819.61	$10.4K → EQR

CBAY vs EQR: Complete Analysis 2026

CBAY — Stock

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Full CBAY Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →

📬

Get this CBAY vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CBAY vs SCHD CBAY vs JEPI CBAY vs O CBAY vs KO CBAY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.